Microbot Medical raises CFO base salary to $288K
Microbot Medical Inc. updated the compensation terms for its Chief Financial Officer, Rachel Vaknin, by entering into Addendum #4 to her Employment Agreement.
Rhea-AI Filing Summary
Microbot Medical Inc. updated the compensation terms for its Chief Financial Officer, Rachel Vaknin, by entering into Addendum #4 to her Employment Agreement. The addendum increases her annual base salary to NIS 864,000, described as the equivalent of $288,000 using a presumed 3:1 NIS-to-U.S. dollar exchange rate. The higher salary is effective as of August 1, 2026. The company characterizes this as a material definitive agreement related to executive employment, and the full terms are set out in the addendum referenced as an exhibit.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 1.01, 5.02, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
CFO annual base salary: NIS 864,000
CFO salary USD equivalent: $288,000
Presumed FX rate: 3:1
+1 more
4 metrics
CFO annual base salary
NIS 864,000
Annual base salary for CFO Rachel Vaknin under Addendum #4, effective August 1, 2026
CFO salary USD equivalent
$288,000
Described equivalent of NIS 864,000 using presumed 3:1 NIS-to-U.S. dollar exchange rate
Presumed FX rate
3:1
Presumed exchange rate of NIS to U.S. dollar used to describe salary equivalent
Common stock par value
$0.01
Par value per share of Microbot Medical Inc. common stock listed on Nasdaq Capital Market
Key Terms
Material Definitive Agreement, Emerging Growth Company, Employment Agreement, Inline XBRL
4 terms
Material Definitive Agreement regulatory
"Entry into a Material Definitive Agreement The information set forth in Item 5.02"
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
Emerging Growth Company regulatory
"405) or Rule 12b-2 of the Securities Exchange Act of 1934 Emerging Growth Company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Employment Agreement financial
"Addendum #4 to Employment Agreement with Rachel Vaknin"
Inline XBRL technical
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What executive compensation change did MBOT disclose for its CFO?
Microbot Medical Inc. increased CFO Rachel Vaknin’s annual base salary to NIS 864,000, described as $288,000 at a 3:1 NIS-to-U.S. dollar exchange rate, through Addendum #4 to her Employment Agreement.
When does the new CFO salary for MBOT become effective?
The updated annual base salary for Microbot Medical’s CFO becomes effective on August 1, 2026. This effective date is specified in the addendum to her Employment Agreement that formalizes the revised compensation terms.
How did MBOT calculate the dollar equivalent of the CFO’s new salary?
Microbot Medical states that the NIS 864,000 annual salary is the equivalent of $288,000, using a presumed 3:1 exchange rate of New Israeli Shekel to U.S. dollar for descriptive purposes.
Which agreement governs the new compensation terms for MBOT’s CFO?
The revised compensation terms for Microbot Medical’s CFO are governed by Addendum #4 to her Employment Agreement, which modifies her existing contract and is identified as an exhibit to the current disclosure.
Does MBOT treat the CFO salary addendum as a material agreement?
Yes. Microbot Medical classifies the CFO’s compensation change as a Material Definitive Agreement, cross-referencing it between the disclosure items addressing significant contracts and executive officer employment arrangements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
